Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its price target lowered by analysts at Cantor Fitzgerald from $3.00 to $2.00. They now have an "overweight" rating on the stock.
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $3.00 price target on the stock.
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $2.50 price target on the stock.